HSA Stops Supply of Eight Brands of Ranitidine Products in Singapore

Eight brands of ranitidine medicines have been found to contain trace amounts of a nitrosamine impurity, N-nitrosodimethylamine (NDMA), which are above the internationally acceptable level. As a precautionary measure, the Health Sciences Authority (HSA) is stopping the sale and supply of the affected ranitidine medicines at clinics, hospitals and pharmacies [see Table A for full list of medicines].

Table A. List of recalled ranitidine-containing products


Product name

Local supplier


Aciloc 150 Tablet 150 mg

Aciloc 300 Tablet 300 mg

Uni Drug House


Apo-Ranitidine Tablet 150 mg

Pharmaforte Singapore Pte Ltd


Hyzan Tablet 150 mg

Apex Pharma Marketing Pte Ltd


Neoceptin R-150 Tablet 150 mg

Pharmatech Resources (FE) Pte Ltd


Vesyca Film Coated Tablet 150 mg

Yung Shin Pharmaceutical (Singapore) Pte Ltd


Xanidine Tablet 150 mg

Polymedic Trading Enterprise Pte Ltd


Zantac Injection 25 mg/ml

Zantac Syrup 150 mg/10 ml

Zantac Tablet 150 mg

GlaxoSmithKline Pte Ltd


Zynol-150 Tablet 150 mg

Naina Mohamed & Sons Private Limited


2     The potential risk of nitrosamines is associated with long term exposure, and patients who have been prescribed with the affected ranitidine medicine for short term use may continue with their medicine. Patients who have any questions about their current treatment can speak to their doctor or pharmacist. There are several other medicines that can be used as alternatives to manage the same conditions.

3     Ranitidine is a medicine used to reduce the production of acid in the stomach in patients with conditions such as heartburn and gastric ulcers. It is generally prescribed for short term use of a few days to a few weeks, and used only when necessary.

4     HSA has tested all locally marketed brands of ranitidine and found trace amounts of the NDMA nitrosamine, that exceeded the internationally acceptable level, in eight brands. Acceptable levels of nitrosamines are set in nanograms (ng), i.e., one billionth of a gram, and is based on what is considered as reasonably safe if a patient continues to take the affected medicine every day for a lifetime of 70 years.

5     In line with the stringent standards set by HSA on the quality of medicines in Singapore, HSA has directed the companies to stop the sale and supply of the affected brands of ranitidine medicines at clinics, hospitals and pharmacies. HSA is also working with the companies supplying these medicines and international regulatory agencies to verify the causes of the contamination, and to identify the necessary measures to address the issue.

About NDMA

6     NDMA is a nitrosamine impurity. Nitrosamines are environmental contaminants and can be found in food or the environment in very minute amounts. For example, NDMA can be found in processed food (pickled vegetables, salted fish, processed meat products such as bacon and sausages). Nitrosamine impurities have recently also been found to be formed unexpectedly during the manufacture of some medicines. Recalls had been undertaken worldwide for affected products found to contain these impurities above the acceptable levels. Studies have reported that exposure over a prolonged period of time to doses of nitrosamine impurities that are much higher than usual human exposure could cause cancer in animals.


Download pdf version here 486 KB

Consumer, Healthcare professional, Industry member, Therapeutic Products

HSA Updates

3 Oct 2019